• 598 Citations
  • 11 h-Index
19992020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research interests

The laboratory of Dr. Daniel Morgan focuses on understanding the mechanisms responsible for the different roles of cannabinoid signaling in human health and disease. One of the lab's main areas of interest is to better understand the mechanisms responsible for tolerance to cannabinoids such as delta-9-tetrahydrocannabinol (∆9-THC) in pathological models of pain including agonist-specific differences in the mechanisms responsible for cannabinoid tolerance. Previous studies have shown that receptor desensitization is involved in the development of tolerance for GPCR-directed agonists in vivo. The laboratory’s work utilizes a novel “knock-in” mouse line that expresses a desensitization-resistant form of the cannabinoid receptor 1 (CB1) to investigate tolerance for ∆9-THC and two synthetic cannabinoid agonists, WIN 55,212-2 and CP55,950. Results from the lab show that tolerance to WIN 55,212-2 is mediated exclusively through this classical mechanism of desensitization, whereas tolerance to ∆9-THC is only partially attenuated when this mechanism is disrupted. Interestingly, data strongly suggests that tolerance to ∆9-THC, but not the other two synthetic agonists, is partially mediated through a c-Jun N-terminal kinase (JNK) signaling pathway. The laboratory is currently engaged in work to better understand the molecular mechanisms responsible for this novel form of JNK-mediated ∆9-THC tolerance. The laboratory is also engaged in a second major project to understand the role of CB1 internalization and trafficking in cannabinoid tolerance and dependence. This project involves using a second “knock-in” mouse that expresses an internalization-deficient form of CB1 to study tolerance and physical dependence for ∆9-THC, WIN 55,212-2 and CP55,950.

Education/Academic qualification

Postdoctoral Training, Indiana Unviersity

20072010

Senior Fellow, University of Washington School of Medicine

20042007

PhD, Rutgers University

19972004

BA, Grinnell College

19931997

External positions

Session Chair and Program Committee, International Cannabinoid Research Society

Jan 1 2018

Session Chair and Program Committee, International Cannabinoid Research Society

2018

Program Committee, Winter Conference on Brain Research

Jan 1 2017Jan 1 2019

Program Committee, Winter Conference on Brain Research

20172019

Neuropharmacology Executive Committee, American Society for Pharmacology and Experimental Therapeutics

Jan 1 2016Jan 1 2019

Neuropharmacology Executive Committee, American Society for Pharmacology and Experimental Therapeutics

20162019

Fingerprint Dive into the research topics where Daniel Morgan is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

Mechanisms of cannabinoid tolerance

Morgan, D. & Guindon, J.

National Institute on Drug Abuse

9/1/187/31/19

Project: Research project

  • Research Output

    • 598 Citations
    • 11 h-Index
    • 24 Article
    • 1 Editorial
    • 1 Short survey
    • 1 Review article

    c-Jun N terminal kinase signaling pathways mediate cannabinoid tolerance in an agonist-specific manner

    Henderson-Redmond, A. N., Nealon, C. M., Davis, B. J., Yuill, M. B., Sepulveda, D. E., Blanton, H. L., Piscura, M. K., Zee, M. L., Haskins, C. P., Marcus, D. J., Mackie, K., Guindon, J. & Morgan, D. J., Mar 1 2020, In : Neuropharmacology. 164, 107847.

    Research output: Contribution to journalArticle

  • Cannabinoids: Current and Future Options to Treat Chronic and Chemotherapy-Induced Neuropathic Pain

    Blanton, H. L., Brelsfoard, J., DeTurk, N., Pruitt, K., Narasimhan, M., Morgan, D. J. & Guindon, J., Jun 1 2019, In : Drugs. 79, 9, p. 969-995 27 p.

    Research output: Contribution to journalReview article

  • 2 Scopus citations

    Tolerance to WIN55,212-2 is delayed in desensitization-resistant S426A/S430A mice

    Nealon, C. M., Henderson-Redmond, A. N., Hale, D. E. & Morgan, D. J., Apr 2019, In : Neuropharmacology. 148, p. 151-159 9 p.

    Research output: Contribution to journalArticle

  • 2 Scopus citations

    Alterations in nociception and morphine antinociception in mice fed a high-fat diet

    Nealon, C. M., Patel, C., Worley, B. L., Henderson-Redmond, A. N., Morgan, D. J. & Czyzyk, T. A., Apr 2018, In : Brain Research Bulletin. 138, p. 64-72 9 p.

    Research output: Contribution to journalArticle

  • 5 Scopus citations

    Increased ethanol drinking in “humanized” mice expressing the mu opioid receptor A118G polymorphism are mediated through sex-specific mechanisms

    Henderson-Redmond, A. N., Lowe, T. E., Tian, X. B. & Morgan, D. J., Apr 2018, In : Brain Research Bulletin. 138, p. 12-19 8 p.

    Research output: Contribution to journalArticle

  • 2 Scopus citations